The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Ustaalioglu, Bala Basak Oven ^a,b   Bilici, Ahmet ^a   Ercan, Serif ^a   Seker, Mesut ^a   Orcun, Asuman ^a   Gumus, Mahmut ^a  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Selimiye Mah Sair Nesimi Sok   (Turkey)

Author keywords

Lung cancer; M30; M65; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M30; MONOCLONAL ANTIBODY M65; PACLITAXEL; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOKERATIN 18; M30 CYTOKERATIN 18 PEPTIDE, HUMAN; M30 CYTOKERATIN-18 PEPTIDE, HUMAN; M65 ANTIGEN, HUMAN; PEPTIDE FRAGMENT;

ADULT; ADVANCED CANCER; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; AGED; BIOSYNTHESIS; BLOOD; DISEASE COURSE; DISEASE FREE SURVIVAL; FOLLOW UP; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATIN-18; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84875343575     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0551-6     Document Type: Article

References (20)

1. Yaman E, Coskun U, Sancak B, Buyukberber S, Ozturk B, Benekli M. Serum M30 levels are associated with survival in advanced gastric carcinoma patients. Int Immunopharmacol. 2010;10:719-22.
2. Ueno T, Toi M, Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother. 2005;59:359-62.
3. Ueno T, Toi M, Bivén K, Bando H, Ogawa T, Linder S. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer. 2003;39:769-74.
4. Kramer G, Erdal H, Mertens HJ, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 2004;64:1751-6.
5. Hickman JA, Beere HM, Wood AC, Waters CM, Parmar R. Mechanism of cytotoxicity caused by antitumor drugs. Toxicol Lett. 1992;64:553-61.
6. Ulukaya E, Karaagac E, Ari F, et al. Chemotherapy increases caspase-cleaved cytokeratin 18 in the serum of breast cancer patients. Radiol Oncol. 2011;45:116-22.
7. Demiray M, Ulukaya E, Arslan M, et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest. 2006;24:669-76.
8. Kramer G, Schwarz S, Hägg M, Havelka AM, Linder S. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer. 2006;94:1592-8.
9. de Haas EC, di Pietro A, Simpson KL, et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia. 2008;10:1041-8.
10. Olofsson MH, Ueno T, Pan Y, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res. 2007;13:3198-206.
11. Bilici A, Ustaalioglu BB, Ercan S, et al. Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer? Cancer Chemother Pharmacol. 2011;68:309-16.
12. Koelink PJ, Lamers CB, Hommes DW, Verspaget HW. Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer. 2009;9:88.
13. Dive C, Smith RA, Garner E, et al. Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer. 2010;102:577-82.
14. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
15. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The levels of caspasecleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer. 2007;56:399-404.
16. Goldstraw P, Crowley J, Chansky K, et al. International association for the study of lung cancer international staging committee; participating institutions. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706-14. Erratum in: J Thorac Oncol. 2007;2:985.
17. James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst. 1999;91:523-8.
18. Green AM, Steinmetz ND. Monitoring apoptosis in real time. Cancer J. 2002;8:82-92.
19. Hou JM, Greystoke A, Lancashire L, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol. 2009;175:808-16.
20. Wu YX, Wang JH, Wang H, Yang XY. Study on expression of Ki-67, early apoptotic protein M30 in endometrial carcinoma and their correlation with prognosis [Article in Chinese]. Zhonghua Bing Li Xue Za Zhi. 2003;32:314-8.